Glucagen Injection Market is predicted to reach at a CAGR of 5.60% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Glucagen Injection Market”. The Glucagen Injection Market is estimated to register a CAGR of 5.60% during the forecast period of 2023 to 2032.

Glucagen Injection Market Highlights

The global Glucagen Injection Market is accounted to register a CAGR of 5.60% during the forecast period and is estimated to reach significant value by 2032.

The Glucagen Injection market is growing due to the rising incidence of hypoglycemia, particularly in diabetic patients. Glucagen is a vital emergency treatment for severe low blood sugar episodes. Increased awareness, a growing diabetic population, and advancements in diabetes management contribute to the market's expansion. Additionally, the ease of administration and the critical role of glucagon in addressing hypoglycemia emergencies further fuel the demand for Glucagen Injections in both healthcare settings and among individuals managing diabetes.

Key Players

MRFR recognizes the following companies as the key players in the global Glucagen Injection Market— Novo Nordisk, Eli Lilly and Company, Xeris Pharmaceuticals, Teva Pharmaceutical Industries, Fresenius SE & Co. KGaA, Xeris Pharmaceuticals Inc, LLC. Zealand Pharma A/S., Avalon Pharma Pvt. Ltd.

Segment Analysis

The global Glucagen Injection Market has been segmented based Application, Age Group, Route of Administration and Distribution Channel.

On the basis of Application, the market is segmented into Therapeutic purpose and Diagnostics purpose. The Therapeutic purpose applications have secured the largest market share in the Glucagen Injection market in 2022, due to their critical role in emergency treatment for severe hypoglycemia.

Based on Age Group, the global Glucagen Injection Market has been segmented into Paediatrics and Adults. The paediatrics age group has secured the largest market share in the Glucagen Injection market in 2022, due to the critical need for rapid blood sugar elevation in paediatric emergency situations such as severe hypoglycemia.

Based on, Route of Administration, the global Glucagen Injection Market has been segmented into Subcutaneous, Intramuscular and Intravenous. The subcutaneous category has secured the largest market share in the Glucagen Injection market in 2022, due to its ease of use and effectiveness in delivering rapid blood sugar elevation.

Based on Distribution Channel, the global Glucagen Injection Market has been segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. The Online pharmacies have secured the largest market share in the Glucagen Injection market in 2022, due to their convenience, accessibility, and ability to reach a broad customer base.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Glucagen Injection Market Research Report

Regional Analysis

The global Glucagen Injection Market, based on region, has been divided into the North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe Glucagen Injection Market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The Glucagen Injection Market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World Glucagen Injection Market comprises of Middle East, Africa, and Latin America.

The largest market share for Nuclear Fuels was maintained by the North American regional sector. North America has captured the largest market share in the Glucagen Injection market due to factors such as a high prevalence of diabetes, well-established healthcare infrastructure, and a significant focus on emergency care. The region's advanced healthcare systems, widespread awareness of diabetes management, and accessibility to emergency medications contribute to the dominance of Glucagen. Additionally, the proactive approach toward diabetes education and the large patient population with diabetes in North America solidify its position as a key consumer of Glucagen injections.

Moreover, the Europe market has been persistently growing over the forecast period. Europe has captured the second-largest market share in the Glucagen Injection market due to factors such as a substantial diabetic population, well-developed healthcare systems, and a proactive approach to emergency care. The region's robust healthcare infrastructure, coupled with high awareness among healthcare professionals and patients, contributes to the significant use of Glucagen. Additionally, stringent regulatory standards ensure the availability and accessibility of Glucagen, solidifying Europe's position as a substantial consumer of emergency hypoglycemia treatment.

The Asia Pacific region is growing at the highest Compound Annual Growth Rate (CAGR) in the Glucagen Injection market due to increasing diabetes prevalence, rising healthcare awareness, and improving healthcare infrastructure. The region's large and diverse population, coupled with a growing emphasis on emergency care and diabetes management, contributes to the robust adoption of Glucagen. As healthcare facilities expand and awareness campaigns intensify, the Asia Pacific region demonstrates significant growth potential, positioning it as a key contributor to the increasing CAGR in the Glucagen Injection market.

Furthermore, the rest of the world's Glucagen Injection Market is divided into the Middle East, Africa, and Latin America. The rest of the world is experiencing growth in the Glucagen Injection market due to expanding healthcare access, increasing diabetes prevalence, and rising awareness of hypoglycemic emergencies. Improved affordability, greater availability of emergency medical interventions, and the growing adoption of diabetes management contribute to market expansion in these regions.

Key Findings of the Study

• The global Glucagen Injection Market is expected to reach USD xx billion by 2032, at a CAGR of 5.60% during the forecast period.


• The Asia Pacific region is the fastest-growing in the Glucagen Injection market due to a rising diabetic population, increasing healthcare awareness, and improving access to emergency medical interventions. These factors contribute to the region's rapid market expansion.


• Based on application, the Therapeutic purpose segment was attributed to holding the largest market in 2022, with an approximate market share of 60–65%.


• Novo Nordisk, Eli Lilly and Company, Xeris Pharmaceuticals, Teva Pharmaceutical Industries, Fresenius SE & Co. KGaA, Xeris Pharmaceuticals Inc, LLC. Zealand Pharma A/S., Avalon Pharma Pvt. Ltd.